Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+)  CD25(-) and CD8(+) T cells attenuates effector function.

Jha SS, Chakraborty NG, Singh P, Mukherji B, Dorsky DI.

Immunology. 2015 May;145(1):124-35. doi: 10.1111/imm.12431.

2.

Mammalian non-classical major histocompatibility complex I and its receptors: Important contexts of gene, evolution, and immunity.

Pratheek BM, Nayak TK, Sahoo SS, Mohanty PK, Chattopadhyay S, Chakraborty NG, Chattopadhyay S.

Indian J Hum Genet. 2014 Apr;20(2):129-41. doi: 10.4103/0971-6866.142855. Review.

3.

Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.

Karimi S, Chattopadhyay S, Chakraborty NG.

Immunology. 2015 Feb;144(2):186-96. doi: 10.1111/imm.12387. Review.

4.

Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.

Chakraborty NG, Yadav M, Dadras SS, Singh P, Chhabra A, Feinn R, Kerr PE, Grant-Kels JM, Mukherji B, Hegde UP.

Hum Immunol. 2013 May;74(5):640-7. doi: 10.1016/j.humimm.2013.01.015. Epub 2013 Feb 4.

PMID:
23391568
5.

T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Kaur N, Naga OS, Norell H, Al-Khami AA, Scheffel MJ, Chakraborty NG, Voelkel-Johnson C, Mukherji B, Mehrotra S.

Cytokine. 2011 Aug;55(2):307-17. doi: 10.1016/j.cyto.2011.04.014. Epub 2011 May 23.

6.

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B; UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity.

Clin Immunol. 2010 Sep;136(3):338-47. doi: 10.1016/j.clim.2010.04.013. Epub 2010 May 23.

7.

The oxazolidinone derivative locostatin induces cytokine appeasement.

Ménoret A, McAleer JP, Ngoi SM, Ray S, Eddy NA, Fenteany G, Lee SJ, Rossi RJ, Mukherji B, Allen DL, Chakraborty NG, Vella AT.

J Immunol. 2009 Dec 1;183(11):7489-96. doi: 10.4049/jimmunol.0901414. Epub 2009 Nov 16.

8.

Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma.

Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, Economou J, Mukherji B.

Clin Dermatol. 2009 Nov-Dec;27(6):603-13. doi: 10.1016/j.clindermatol.2008.09.019. Review.

PMID:
19880048
9.

GITR expression on T-cell receptor-stimulated human CD8 T cell in a JNK-dependent pathway.

Chattopadhyay S, Chakraborty NG.

Indian J Hum Genet. 2009 Sep;15(3):121-4. doi: 10.4103/0971-6866.60188.

10.

Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S.

Cancer Res. 2009 Aug 1;69(15):6282-9. doi: 10.1158/0008-5472.CAN-09-1176. Epub 2009 Jul 28.

11.

Immunoregulation through IL-10 gene expression and the fate of cytotoxic T lymphocyte-mediated tumor immunotherapy.

Chakraborty NG.

Indian J Hum Genet. 2009 Jan;15(1):3-8. doi: 10.4103/0971-6866.50862.

12.

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.

Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B.

J Immunol. 2008 Jul 15;181(2):1063-70.

13.
14.

Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Chhabra A, Chakraborty NG, Mukherji B.

Clin Immunol. 2008 Mar;126(3):251-9. doi: 10.1016/j.clim.2007.11.011. Epub 2008 Jan 14.

15.

Genetically predisposed, life style and occurrence of metastatic cancer.

Chakraborty NG.

Indian J Hum Genet. 2007 May;13(2):48-9. doi: 10.4103/0971-6866.34705. No abstract available.

16.

Macrophages as stimulators of MART-1 27-35 epitope-specific human cytolytic T lymphocytes in vitro.

Mehrotra S, Zaidi N, Chakraborty NG, Mukherji B.

Pathobiology. 2006;73(5):238-43.

PMID:
17314494
17.

Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor.

Chhabra A, Mehrotra S, Chakraborty NG, Dorsky DI, Mukherji B.

Eur J Immunol. 2006 Dec;36(12):3167-74.

18.

Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death.

Mehrotra S, Chhabra A, Hegde U, Chakraborty NG, Mukherji B.

J Leukoc Biol. 2007 Feb;81(2):539-47. Epub 2006 Oct 24.

PMID:
17062604
19.

Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro.

Chattopadhyay S, Mehrotra S, Chhabra A, Hegde U, Mukherji B, Chakraborty NG.

J Immunol. 2006 Jan 15;176(2):984-90.

20.

Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL.

Chattopadhyay S, Chakraborty NG.

Hum Immunol. 2005 Aug;66(8):884-91. Epub 2005 Jul 20.

PMID:
16216672
21.

Regulatory T cells and tumor immunity.

Chattopadhyay S, Chakraborty NG, Mukherji B.

Cancer Immunol Immunother. 2005 Dec;54(12):1153-61. Epub 2005 May 3. Review.

PMID:
15868167
22.

Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells.

Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG.

Immunology. 2004 Dec;113(4):472-81.

23.

Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.

Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B.

J Immunol. 2004 Nov 15;173(10):6017-24.

24.

Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.

Chhabra A, Mehrotra S, Chakraborty NG, Mukherji B, Dorsky DI.

Eur J Immunol. 2004 Oct;34(10):2824-33.

25.

Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.

Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B.

Hum Immunol. 2004 Aug;65(8):794-802.

PMID:
15336780
26.

Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro.

Mehrotra S, Stevens R, Zengou R, Chakraborty NG, Butterfield LH, Economou JS, Dorsky DI, Mukherji B.

Cancer Res. 2003 Sep 1;63(17):5607-14.

27.

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.

Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC.

Cancer Immunol Immunother. 2003 Aug;52(8):497-505. Epub 2003 Jun 3.

PMID:
12783216
28.

Stimulatory and inhibitory maturation of human macrophage-derived dendritic cells.

Chakraborty A, Li L, Chakraborty NG, Mukherji B.

Pathobiology. 1999;67(5-6):282-6.

PMID:
10725803
29.

Stimulatory and inhibitory differentiation of human myeloid dendritic cells.

Chakraborty A, Li L, Chakraborty NG, Mukherji B.

Clin Immunol. 2000 Feb;94(2):88-98.

PMID:
10637093
30.
31.

Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.

Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD, Edwards RL, Dorsky D, Clive J, Mukherji B, Tutschka PJ.

Bone Marrow Transplant. 1999 Mar;23(5):469-74.

32.

Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.

Pérez-Díez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B.

Cancer Res. 1998 Dec 1;58(23):5305-9.

33.

Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS.

J Immunol. 1998 Nov 15;161(10):5607-13.

34.

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma.

Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase H, Ergin MT, Mukherji B.

Cancer Immunol Immunother. 1998 Sep;47(1):58-64.

PMID:
9755879
35.

Human melanoma-specific, noncytolytic CD8+ T cells that can synthesize type I cytokine.

Chakraborty NG, Mukherji B.

Cancer Res. 1998 Apr 1;58(7):1363-6.

36.
37.
38.

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, et al.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078-82.

39.

Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients.

Yamasaki S, Okino T, Chakraborty NG, Adkisson WO, Sampieri A, Padula SJ, Mauri F, Mukherji B.

Cancer Immunol Immunother. 1995 Apr;40(4):268-71.

PMID:
7750125
40.

Immunobiology and immunotherapy of melanoma.

Mukherji B, Chakraborty NG.

Curr Opin Oncol. 1995 Mar;7(2):175-84. Review.

PMID:
7756383
41.

Age related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients. A comparative in vitro study with interleukin-2.

Chakraborty A, Chakraborty NG, Chattopadhyay U.

Tumori. 1994 Jun 30;80(3):233-7. Erratum in: Tumori 1995 May-Jun;81(3):following 224.

PMID:
8053083
42.

Inhibition of interleukin-2 synthesis and interleukin-2 receptor alpha expression on T cells by a cell-free factor derived from a CD4+ regulatory T cell clone.

Okino T, Chakraborty NG, Stabach P, Twardzik DR, Padula SJ, Mukherji B.

Clin Immunol Immunopathol. 1993 Sep;68(3):256-62.

PMID:
8103719
43.

Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in SCID mice.

Chakraborty NG, Okino T, Stabach P, Padula SJ, Yamase H, Morse E, Sha'afi RI, Twardzik DR, Shultz LJ, Mukherji B.

In Vivo. 1991 Nov-Dec;5(6):609-14.

PMID:
1810447
44.
45.

Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes.

Chakraborty NG, Sporn JR, Pasquale DR, Ergin MT, Mukherji B.

Clin Immunol Immunopathol. 1991 Jun;59(3):407-16.

PMID:
2029793
46.
47.

Platinum in blood mononuclear cells from patients after cisplatin therapy.

Sunderman FW Jr, Sporn J, Hopfer SM, Sweeney KR, Chakraborty NG, Greenberg B.

Ann Clin Lab Sci. 1990 Nov-Dec;20(6):379-84.

PMID:
2073087
48.

Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response.

Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B.

J Immunol. 1990 Oct 1;145(7):2359-64.

PMID:
1975829
49.

T-cell clones that react against autologous human tumors.

Mukherji B, Chakraborty NG, Sivanandham M.

Immunol Rev. 1990 Aug;116:33-62. Review.

PMID:
2146210
50.

Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.

Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT.

J Exp Med. 1989 Jun 1;169(6):1961-76.

Supplemental Content

Loading ...
Support Center